Vaxcyte (PCVX) Conducts Initial Dosage for VAX-A1 Phase 1 Study

Vaxcyte Inc. (NASDAQ:PCVX) is one of the 10 best mid-cap stocks that could double your money.

On June 3, Vaxcyte Inc. (NASDAQ:PCVX) announced that the first participant was dosed in the Phase 1, first-in-human study evaluating VAX-A1. This is the company’s investigational prophylactic vaccine candidate for the prevention of disease caused by Group A Streptococcus in healthy adults aged 18 to 40 years.

Copyright: iggyphoto / 123RF Stock Photo

The company anticipates reporting topline data from the study in the second half of 2027. The primary objective of the randomized, double-blind, placebo-controlled, dose-escalation, two-stage study is to assess the safety and tolerability of VAX-A1, while the secondary objective is to evaluate initial immunogenicity data.

Stage 1 will evaluate three dose levels compared to a placebo in approximately 12 adults. Following independent Data Safety Monitoring Board approval, Stage 2 will evaluate the same dose levels in approximately 68 adults.

Speaking about this development, Grant Pickering, CEO and Co-Founder of Vaxcyte, stated that initiation of the study represents an important milestone in addressing a significant global public health challenge with no approved vaccine. Furthermore, Jim Wassil, EVP and COO, noted that Group A Strep is responsible for a wide spectrum of diseases.

Vaxcyte Inc. (NASDAQ:PCVX) is a company involved in the development of next-generation vaccines that offer protection against threatening bacterial diseases. Currently a clinical-stage company, Vaxcyte Inc. (NASDAQ:PCVX) deploys innovative synthetic methods and advanced chemistry to produce complex, high-fidelity vaccines that contain enhanced immunological benefits.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.